ospemifene
Sign in to saveAlso known as FC-1271, Osphena®, Senshio®, 2-(4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol, 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol, Deamino-hydroxytoremifene, FC-1271a, 2-(P-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
Ospemifene (brand names Osphena and Senshio produced by Shionogi) is an oral medication indicated for the treatment of dyspareuniapain during sexual intercourseencountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by vulvovaginal atrophy.
Key facts
- Drug.image
- Ospemifene.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Osphena, Senshio
- Drug.MedlinePlus
- a613039
- Drug.DailyMedID
- Ospemifene
- Drug.routes_of_administration
- By mouth
- Drug.class
- Selective estrogen receptor modulator
- Drug.ATC_prefix
- G03
- Drug.ATC_suffix
- XC05
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 128607-22-7
- Drug.PubChem
- 3036505
- Drug.DrugBank
- DB04938
- Drug.ChemSpiderID
- 2300501
- Drug.UNII
- B0P231ILBK
via Wikipedia infobox
Research
295 papers- Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection.International journal of women's health · 2024
- The 2022 hormone therapy position statement of The North American Menopause Society.Menopause (New York, N.Y.) · 2022
- Ospemifene efficacy and safety data in women with vulvovaginal atrophy.Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2020
- Effects of ospemifene on bone in postmenopausal women.Climacteric : the journal of the International Menopause Society · 2019
- Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.Expert review of endocrinology & metabolism · 2019
via PubMed
Wikidata facts
- Mass
- 378.138658
Show 4 more facts
- chemical formula
- C₂₄H₂₃ClO₂
- canonical SMILES
- C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=C(C=C3)OCCO)CCCl
- isomeric SMILES
- C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCO)/CCCl
- Commons category
- Ospemifene
via Wikidata · CC0
~7 min read
Article
12 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Approval process
- Preclinial and clinical trials
- Society and culture
- Economics
- References
Ospemifene (brand names Osphena and Senshio produced by Shionogi) is an oral medication indicated for the treatment of dyspareuniapain during sexual intercourseencountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by vulvovaginal atrophy.
The medication was approved by the US Food and Drug Administration in February 2013, and by the European Medicines Agency for marketing in the European Union in January 2015.
Available in 10 languages
via Wikidata sitelinks · CC0